A compound drug for preventing and treating porcine reproductive and respiratory syndrome

Abstract

The present invention relates to a compound drug for preventing and treating porcine reproductive and respiratory syndrome (PRRS), belonging to the field of veterinary drugs. The present invention makes an oral pharmaceutical preparation by mixing an animal-specific macrolide drug, sodium houttuyfonate, mannan oligosaccharide peptide and pharmaceutical excipients in a certain proportion. The drug of the present invention can effectively treat acute-phase PRRS, rapidly relieve the clinical symptoms of diseased pigs and improve the survival rate.

Description

Technical Field

[0001] The present invention belongs to the field of veterinary drugs, and particularly relates to a compound drug for preventing and treating porcine reproductive and respiratory syndrome (PRRS). Background Art

[0002] Porcine reproductive and respiratory syndrome virus (PRRSV) is a highly contagious disease showing endemic prevalence. PRRSV only infects pigs, and pigs of various breeds, different ages and uses can be infected, but pregnant sows and piglets within 1 month old are the most susceptible.

[0003] After the invasion of the porcine reproductive and respiratory syndrome virus into pigs, it will damage the immune systems of various parts of the pig body, especially having a very adverse effect on the cultivation of porcine alveolar macrophages. This will lead to the emergence of other complications, such as fibrinous serositis, arthritis, paratyphoid and other diseases. At the same time, the destruction of the immune system makes the effect of vaccine injection unable to be exerted, severely restricting the yield and quality of pigs. Since the virus stays in the body for a long time after the pig herd is infected, and due to the rapid and extensive spread of the toxicity, the toxins remaining in the pig farm cannot be completely removed, easily resulting in the occurrence of persistent infection.

[0004] At present, there is no specific therapeutic drug for porcine reproductive and respiratory syndrome. In addition, for vaccination, generally speaking, there is no very effective immune prevention and control measure nowadays, and the phenomenon of the reversion of virulence and the safety problem of PRRS attenuated live vaccine are increasingly causing people's concerns. There have been many outbreaks of PRRS in pig herds caused by the use of attenuated live vaccines at home and abroad. At the same time, porcine reproductive and respiratory syndrome often secondary to classical swine fever, swine infectious pleuropneumonia, swine pasteurellosis, swine eperythrozoonosis and other diseases.

[0005] Macrolide antibiotics are a general term for antibacterial drugs with a 12-16 carbon lactone ring in the molecular structure. They inhibit bacterial protein synthesis by blocking the activity of peptidyl transferase in the 50s ribosome and belong to rapid bacteriostatic agents. They are mainly used for the treatment of aerobic gram-positive cocci and negative cocci, certain anaerobic bacteria, as well as legionella, mycoplasma, chlamydia and other infections. Research shows that in addition to the antibacterial effect, macrolide antibiotics also have immune regulation and anti-inflammatory effects. Macrolide antibacterial drugs can carry out immune regulation by regulating the functions of cells (including tissue cells, immune cells and inflammatory cells). Research shows that macrolide antibacterial drugs have a regulatory effect on the secretion of cytokines and have a certain anti-inflammatory effect. Macrolide antibiotics can be used to treat secondary bacterial infections of porcine reproductive and respiratory syndrome, but have poor effects on the acute stage of porcine reproductive and respiratory syndrome.

[0006] Sodium houttuyfonate can increase the level of serum properdin and enhance the phagocytic ability of white blood cells, thereby improving the body's non-specific immunity to resist the invasion of pathogens. It is currently commonly used in the treatment of respiratory inflammatory diseases in humans such as chronic bronchitis and pneumonia. Mannan peptide can increase peripheral white blood cells, enhance the phagocytic function of the reticuloendothelial system, activate macrophages and lymphocytes, induce thymus lymphocytes to produce active substances, and improve and enhance the body's immune function and stress ability. It can induce the production of a variety of effector cells and cytokines to produce a "cytokine cocktail" effect, and can kill viruses and pathogenic bacteria broadly for the treatment of various viral and pathogenic bacterial infections, recurrent respiratory infections, chronic bronchitis, etc. There is currently no relevant report indicating that sodium houttuyfonate and mannan peptide can effectively treat porcine reproductive and respiratory syndrome (PRRS). Summary of the Invention

[0007] In order to solve the above technical problems, the purpose of the present invention is to provide a compound drug for preventing and treating porcine reproductive and respiratory syndrome (PRRS).

[0008] The purpose of the present invention is achieved through the following technical solutions:

[0009] The present invention provides a compound drug for treating porcine reproductive and respiratory syndrome (PRRS), which is made from macrolide drugs, sodium houttuyfonate, mannan peptide and pharmaceutical excipients;

[0010] Preferably, the macrolide drugs include but are not limited to tilmicosin, tylosin, tiamulin, tildipirosin, tulathromycin and their salts;

[0011] Furthermore, the compound drug for treating porcine reproductive and respiratory syndrome (PRRS) is made from 10 - 80 parts of macrolide drugs, 0.1 - 10 parts of sodium houttuyfonate, 0.1 - 10 parts of mannan peptide and 18 - 80 parts of pharmaceutical excipients;

[0012] Furthermore, the compound drug for treating porcine reproductive and respiratory syndrome (PRRS) is made from 20 - 60 parts of macrolide drugs, 1 - 8 parts of sodium houttuyfonate, 1 - 5 parts of mannan peptide and 20 - 66 parts of pharmaceutical excipients;

[0013] Furthermore, the compound drug for treating porcine reproductive and respiratory syndrome (PRRS) is made from 30 - 50 parts of macrolide drugs, 2.5 - 5 parts of sodium houttuyfonate, 2.5 - 5 parts of mannan peptide and 50 - 64 parts of pharmaceutical excipients;

[0014] Preferably, the pharmaceutical excipients include but are not limited to starch, corncob powder, dextrin, purified water, anhydrous glucose, sucrose;

[0015] Furthermore, the dosage form of the compound drug for treating porcine reproductive and respiratory syndrome (PRRS) can be a premix, powder, granule, oral liquid veterinary drug preparation;

[0016] Compared with the prior art, the beneficial effects of the present invention are:

[0017] The present invention makes an oral pharmaceutical preparation by mixing macrolide drugs specific for animals, sodium houttuyfonate, and mannanoligosaccharide peptide in a certain proportion, which solves the problem that the single use of macrolide drugs can only treat secondary infections but has poor effects on the acute phase of porcine reproductive and respiratory syndrome (PRRS), especially having excellent effects on the respiratory symptoms caused by PRRS. Through experimental verification, the drug of the present invention can effectively treat the acute phase of PRRS, quickly relieve the clinical symptoms of diseased pigs, and improve the survival rate. Specific Embodiments

[0018] The present invention will be more specifically described by the following examples, but it should be understood that the examples are only for illustrating the present invention and do not limit the scope of the present invention in any way.

[0019] Example 1

[0020] Prescription:

[0021] Prescription ingredients Prescription quantity Tilmicosin 400g Sodium houttuyfonate 50g Mannatide 50g Starch 500g

[0022] Preparation method:

[0023] Weigh the prescription amounts of tilmicosin, sodium houttuyfonate, mannanoligosaccharide peptide, and starch, mix them evenly to obtain the powder of the drug.

[0024] Example 2

[0025] Prescription:

[0026] Prescription ingredients Prescription quantity Tylosin tartrate 800g Sodium houttuyfonate 10g Mannatide 10g Corn cob powder 180g

[0027] Preparation method:

[0028] Weigh the prescription amounts of tylosin tartrate, sodium houttuyfonate, mannanoligosaccharide peptide, and corncob powder, mix them evenly to obtain the premix of the drug.

[0029] Example 3

[0030] Prescription:

[0031] Prescription ingredients Prescription quantity Tyvallate 600g Sodium houttuyfonate 100g Mannatide 100g Dextrin 200g

[0032] Preparation method:

[0033] Weigh the prescription amounts of tiamulin fumarate, sodium houttuyfonate, mannanoligosaccharide peptide, and dextrin, mix them evenly, make soft materials, granulate, and dry to obtain the granules of the drug.

[0034] Example 4

[0035] Prescription:

[0036] Prescription ingredients Prescription quantity Tilmicosin phosphate 100g Sodium houttuyfonate 50g Mannatide 50g Purified water 800g

[0037] Preparation method:

[0038] Weigh the prescribed amounts of tilmicosin phosphate, sodium houttuyfonate, and mannan peptide, add them to purified water, stir to dissolve, filter, and fill to obtain the oral liquid of the drug.

[0039] Example 5

[0040] Prescription:

[0041] Prescription ingredients Prescription quantity Tylosin phosphate 200g Sodium houttuyfonate 1g Mannatide 10g Anhydrous glucose 789g

[0042] Preparation method:

[0043] Weigh the prescribed amounts of tylosin tartrate, sodium houttuyfonate, mannan peptide, and anhydrous glucose, mix them evenly to obtain the powder of the drug.

[0044] Example 6

[0045] Prescription:

[0046] Prescription ingredients Prescription quantity Tildipirosin 500g Sodium houttuyfonate 80g Mannatide 1g Starch 419g

[0047] Preparation method:

[0048] Weigh the prescribed amounts of tildipirosin, sodium houttuyfonate, mannan peptide, and starch, mix them evenly to obtain the powder of the drug.

[0049] Example 7

[0050] Prescription:

[0051] Prescription ingredients Prescription quantity Tulathromycin 300g Sodium houttuyfonate 50g Mannatide 10g Dextrin 640g

[0052] Preparation method:

[0053] Weigh the prescribed amounts of tulathromycin, sodium houttuyfonate, mannan peptide, and dextrin, mix them evenly to obtain the powder of the drug.

[0054] Example 8

[0055] Prescription:

[0056] Prescription ingredients Prescription quantity Tilmicosin phosphate 250g Sodium houttuyfonate 40g Mannatide 50g Dextrin 660g

[0057] Preparation method:

[0058] Weigh the prescribed amounts of tilmicosin phosphate, sodium houttuyfonate, mannan peptide, and dextrin, mix them evenly, make soft materials, granulate, and dry to obtain the granules of the drug.

[0059] Example 9

[0060] Prescription:

[0061] Prescription ingredients Prescription quantity Tylosin 550g Sodium houttuyfonate 25g Mannatide 25g Sucrose 400g

[0062] Preparation method:

[0063] Weigh the prescription amount of tylosin, sodium houttuyfonate, mannan peptide, and sucrose, mix them evenly to obtain the powder of the drug.

[0064] Test Example 1 Clinical efficacy test of the drug prepared according to Example 1

[0065] Test method: Select 60 finishing pigs with natural infection, showing respiratory symptoms, dyspnea, sometimes abdominal breathing, loss of appetite or anorexia, body temperature rising above 40°C, rough hair, ataxia, emaciation, eyelid edema, purple skin on the ears and body surface, etc., and positive serological antibodies against PRRSV, with a body weight of less than 50 kg. Randomly divide them into 6 groups, namely Group I, Group II, Group III, Group IV, Group V, and Group VI, with 10 pigs in each group.

[0066] Test drugs:

[0067] Group I (test drug group): The drug prepared according to Example 1

[0068] Group II (control drug group): 50 parts of sodium houttuyfonate, 50 parts of mannan peptide, and 900 parts of starch, mix them evenly to obtain.

[0069] Group III (control drug group): 400 parts of tilmicosin, 50 parts of sodium houttuyfonate, and 550 parts of starch, mix them evenly to obtain.

[0070] Group IV (control drug group): 400 parts of tilmicosin, 50 parts of mannan peptide, and 550 parts of starch, mix them evenly to obtain.

[0071] Group V (control drug group): 400 parts of tilmicosin and 600 parts of starch, mix them evenly to obtain.

[0072] Group VI: Blank control group.

[0073] Drug administration method: For the test drug group and the control drug group, administer the drug by mixing it with feed. Mix 1 kg of the drug with 2 tons of feed and use it continuously for 7 days. The blank control group is not given the drug.

[0074] Efficacy judgment: Disappearance of symptoms and negative serum turn positive means cure.

[0075] Test results: The clinical efficacy test results of the drug prepared according to Example 1 are shown in Table 1

[0076]

[0077] Test conclusion: The compound drug of the present invention has a significantly better therapeutic effect on porcine reproductive and respiratory syndrome than the compound preparation of two drugs and the single preparation of tilmicosin. The compound drug of the present invention has a good therapeutic effect on porcine reproductive and respiratory syndrome when administered by mixing it with feed.

[0078] Test Example 2 Clinical Pharmacodynamic Test of Preparing Drugs According to Example 7

[0079] Test method: Select 30 sows with natural infection, respiratory symptoms, dyspnea, sometimes abdominal breathing, anorexia or refusal to eat, body temperature rising above 40°C, rough hair, ataxia, emaciation, eyelid edema, purple skin on ears and body surface, etc., and positive serological antibodies against PRRSV. Randomly divide them into 3 groups, namely Group I, Group II, and Group III, with 10 heads in each group.

[0080] Test drugs:

[0081] Group I (test drug group): The drug prepared according to Example 7

[0082] Group II (control drug group): 250 parts of tilmicosin phosphate and 750 parts of dextrin are mixed evenly, made into soft material, granulated, and dried to obtain the granule of the drug.

[0083] Group III: Blank control group.

[0084] Drug administration method: The test drug group and the control drug group are administered by drinking water. For every 1 kg of drug, 2 tons of water are added, and it is used continuously for 7 days. The blank control group is not administered.

[0085] Efficacy judgment: Disappearance of symptoms and negative serum indicate cure.

[0086] Test results: The clinical pharmacodynamic test results of the drug prepared according to Example 7 are shown in Table 2

[0087]

[0088]

[0089] Test conclusion: The compound drug of the present invention has a significantly better therapeutic effect on porcine reproductive and respiratory syndrome than the single preparation of tilmicosin phosphate, and has a good therapeutic effect on porcine reproductive and respiratory syndrome when administered by drinking water.

[0090] Test Example 3 Comparison of Clinical Pharmacodynamic Tests of Preparing Drugs According to Examples 1, 2, 3, 6, and 7

[0091] Test method: Select 60 fattening pigs with natural infection, respiratory symptoms, dyspnea, sometimes abdominal breathing, anorexia or refusal to eat, body temperature rising above 40°C, rough hair, ataxia, emaciation, eyelid edema, purple skin on ears and body surface, etc., and positive serological antibodies against PRRSV. Randomly divide them into 6 groups, namely Group I, Group II, Group III, Group IV, Group V, and Group VI, with 10 heads in each group.

[0092] Test drugs:

[0093] Group Ⅰ - Group Ⅴ (experimental drug groups): drugs prepared according to Examples 1, 2, 3, 6, and 7 respectively.

[0094] Group Ⅵ: blank control group.

[0095] Drug administration method: For the experimental drug groups, mixed feed administration. Calculated by the active drug, 2 tons of feed are mixed with 400 g of the active drug and administered for 7 consecutive days. The blank control group is not administered.

[0096] Efficacy judgment: Disappearance of symptoms and negative conversion of serum indicate cure.

[0097] Test results: The clinical pharmacodynamic test results of the drugs prepared according to Examples 1, 2, 3, 6, and 7 are shown in Table 3

[0098]

[0099] Test conclusion: The compound drug of the present invention has an obvious therapeutic effect on porcine reproductive and respiratory syndrome. When tilmicosin or tiamulin is a macrolide drug, the effect of the compound drug composition is better.

Claims

1. A compound drug for treating porcine reproductive and respiratory syndrome, characterized in that, It is made of 30-50 parts of macrolide drugs, 2.5-5 parts of sodium houttuyfonate, 2.5-5 parts of mannan peptide, and 50-64 parts of pharmaceutical excipients; the macrolide drugs are tilmicosin, tylosin, tiamulin, tedizolid and their salts.

2. The compound medicine for treating porcine reproductive and respiratory syndrome according to claim 1, wherein The pharmaceutical excipients are starch, corncob powder, dextrin, purified water, anhydrous glucose, sucrose.

3. The compound medicine for treating porcine reproductive and respiratory syndrome according to claim 1, wherein, The dosage form of the compound drug for treating porcine reproductive and respiratory syndrome is powder, granule, oral liquid.

Images